

Uceris[®] (budesonide) – First-time generic

- On April 28 2023, [Padagis launched](#) an [AB-rated](#) generic version of Bausch Health's [Uceris \(budesonide\)](#) rectal foam.
 - The FDA granted Padagis' generic Uceris 180-days of competitive generic therapy exclusivity.
- Uceris is approved for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.
- Uceris is also available generically as an oral [extended-release tablet](#) approved for the induction of remission in patients with active, mild to moderate ulcerative colitis.
- According to IQVIA, annual sales for Uceris were approximately \$13 million in the 12 months ended March 2023.